The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Rosuvastatin (Rozucor (10 mg)) is used to reduce ...

London, United Kingdom, Monday 6 September 2004. New data from the first international prospective study of statin treatment in people with the metabolic syndrome demonstrate that CRESTOR TM ...

Stockholm, Sweden - New data comparing the efficacy of atorvastatin (Lipitor® - Pfizer) and rosuvastatin (Crestor® - AstraZeneca) suggest the new statin had incremental benefit in lowering LDL over ...

A head-to-head comparison of two popular lipid-lowering medications suggests that rosuvastatin may be a better option than atorvastatin when it comes to decreasing the risk of all-cause mortality and ...

Kyoto, Japan, Monday 29 September 2003. New data presented at the XIIIth International Symposium on Atherosclerosis (ISA) show AstraZeneca's highly effective statin CRESTOR (rosuvastatin) achieves ...

Savannah, GA - An open-label, randomized trial has shown that 10 mg of rosuvastatin (Crestor, AstraZeneca) significantly reduced high-sensitivity C-reactive protein (hs-CRP) levels in a group of ...

Crestor logo image Crestor (rosuvastatin calcium; AstraZeneca) tablets have been approved for use in pediatric patients aged 7-17 years with homozygous familial hypercholesterolemia (HoFH) to reduce ...

Efficacy of switching statin therapy from generic simvastatin was examined in a VA population. Ezetimibe/simvastatin was more potent than atorvastatin or rosuvastatin in lowering LDL. Treatment of ...

Althera announced the FDA approved its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of elevated LDL in adults with primary nonfamilial hyperlipidemia or homozygous familial ...

New data from the CORONA study presented today at the American Heart Association 2007 Scientific Sessions in Orlando, US, showed that adding a statin to optimised heart failure treatment did not ...

LONDON, September 6 /PRNewswire/ -- AstraZeneca today announced enrolment of the first patient in the new GRAVITY study (Gauging the lipid effects of RosuvAstatin plus ezetimibe Versus sImvastatin ...